About Bare Metal Stents
A BMS is a stent without a coating or covering. It consists of a mesh-like tube with a thin wire. These stents are made up of stainless steel, cobalt chromium alloy, or other high-grade metals. The structure of a BMS looks like a metallic coil or a tubular mesh. The devices differ from each other with respect to composition, delivery system, and architectural design. They have different strut patterns and widths, stent lengths, radial strength, stent diameters, radiopacity, thrombogenicity, and magnetic resonance imaging compatibility.
Technavio’s analysts forecast the global bare metal stents market to grow at a CAGR of 1.38% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bare metal stents market for 2017-2021. To calculate the market size, the report considers the net sales and the revenue generated from it.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bare Metal Stents Market 2017-2021
Technavio recognizes the following companies as the key players in the global bare metal stents market: Abbott, Boston Scientific, and Medtronic
Other Prominent Vendors in the market are: Alvimedica, B. Braun Medical, Balton, Biosensors International, BIOTRONIK, ENDOCOR, Meril Life Sciences, MicroPort Scientific, ORBUSNEICH, RONTIS, and Terumo Medical.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Increasing number of cath labs. The cath labs are equipped with advanced diagnostic imaging systems that are used to visualize arteries and chambers of the heart. These labs mainly conduct tests and procedures for angioplasty, angiogram, and pacemaker implantation. They are now being equipped with the latest imaging technologies to diagnose and treat the CVDs.”
According to the report, one of the major drivers for this market is Increasing awareness about risks associated with CVDs. The awareness level among people about CVDs has been increasing, and they are more focused on living a healthy lifestyle. The awareness about CVDs among general public had been increased from 30% in 1997 to 54% in 2009.
Further, the report states that one of the major factors hindering the growth of this market is Increasing development of BRS. The BRS offers several potential advantages over BMS, which includes less stent thrombosis, less dual antiplatelet therapy, and improving lumen modeling. Several companies are developing the BRS. Around 15 BRS programs are in progress, with five in advanced development stages and two having received Conformité Européene (CE) Mark approval. The companies have been focusing on BRS due to its several advantages.
Abbott, Boston Scientific, and Medtronic, Alvimedica, B. Braun Medical, Balton, Biosensors International, BIOTRONIK, ENDOCOR, Meril Life Sciences, MicroPort Scientific, ORBUSNEICH, RONTIS, and Terumo Medical.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook